← Back to all trials
Not Yet Recruiting
NCT07854990
Clinical Predictors and Therapeutic Gaps in CKM Syndrome Among Adults With Type 2 Diabetes
Conditions: Type 2 Diabetes Mellitus, Cardiovascular-Kidney-Metabolic Syndrome, Diabetic Kidney Disease
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 231
Sponsor: Assiut University
Location: Assiut university Asyut Abutig
Summary
Type 2 diabetes (T2D) is a principal driver of cardiovascular-renal-metabolic (CKM) syndrome, where metabolic, renal, and cardiac dysfunction accelerate disease progression. This cross-sectional study aims to classify adult patients with T2D attending outpatient clinics at Assiut University Hospitals across CKM stages (0-4) according to the 2023 American Heart Association (AHA) staging system. Additionally, the study identifies independent clinical and laboratory predictors of advanced CKM stages (Stages 3-4) and quantifies the therapeutic gap regarding guideline-indicated organ-protective medications (SGLT2 inhibitors, GLP-1 receptor agonists, RAAS inhibitors, statins, and MRAs).
Eligibility Criteria
Inclusion Criteria:
* Adults aged 18 years or older.
* Established diagnosis of type 2 diabetes mellitus (ADA criteria) for at least 6 months with diabetic kidney disease (DKD), obesity, or cardiac affection.
* Willing and able to give written informed consent.
Exclusion Criteria:
* Type 1 or secondary diabetes.
* Already on chronic dialysis or with a functioning kidney transplant.
* Pregnancy.
* Active malignancy or terminal illness with life expectancy \
Source: ClinicalTrials.gov (NCT07854990). StuddyBuddy aggregates publicly available trial information.
